ASH 2021: A Focus on Leukemia & Lymphoma
Focus on Lymphoma Leukemia
ASH 2021
Ibrutinib Continues to Outperform Chemoimmunotherapy in Patients With Treatment-Naïve CLL
Ibrutinib was associated with prolonged progression-free survival (PFS) compared to the chemoimmunotherapy regimen bendamustine plus rituximab in older patients with treatment-naïve chronic lymphocytic leukemia (CLL). In...
Patients With Non-Hodgkin’s Lymphoma Subtypes Incur High Hospital Costs
According to published data, patients with mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL) experience frequent relapses over the course of...
Venetoclax/Idelalisib Regimens Better Option After First-Line Ibrutinib for CLL/SLL
The establishment of ibrutinib as a preferred first-line treatment option makes it important to understand the treatment sequence following first-line ibrutinib and the patient characteristics of those treated with a second-line...
Delayed Start of Therapy Feasible in Some Patients With MCL
Currently, the effect of the diagnosis-to-treatment interval (DTI) on survival in patients with mantle cell lymphoma (MCL) has not been extensively examined. Researchers aimed to determine the feasibility of active surveillance...
Addition of Ibrutinib to Chemoimmunotherapy in CLL
The combination of fludarabine, cyclophosphamide, and rituximab (FCR) is the only regimen other than allotransplantation shown in studies to result in a significant chance of functional cure in very long-term follow-up for...
Phase 3 GLOW: first-line ibrutinib plus venetoclax improves outcomes in elderly or unfit CLL
With an updated median follow-up of 34.1 months, the 30-month progression-free survival (PFS) was 80.5% with ibrutinib plus venetoclax versus 35.8% for chlorambucil plus obinutuzumab in elderly or unfit patients with chronic...
CAPTIVATE: Ibrutinib plus venetoclax show stunning efficacy in CLL
The first-line, chemotherapy-free regimen of ibrutinib plus venetoclax showed ongoing efficacy after 2 years of follow-up in patients with chronic lymphocytic leukemia (CLL). Patients with confirmed undetected Minimal Residual...
Reduced risk of Alzheimer’s disease in CHIP carriers
Clonal hematopoiesis of indeterminate potential (CHIP) was related to decreased risk of Alzheimer’s disease (AD) and AD neuropathological changes. Mutated hematopoietic stem cells were detected in the brains of CHIP carriers....
UKALL 2003: therapy de-escalation safe in low-risk MRD patients with ALL
Therapy de-escalation in patients with acute lymphoblastic leukemia (ALL) and a low-risk minimal residual disease (MRD) profile was safe, 10-year follow-up results of the UKALL 2003 trial show. Patients with a high-risk MRD...
Heavily pre-treated FLT3-mutated AML population may benefit from novel triplet regimen
A combination treatment of quizartinib plus venetoclax plus decitabine was highly active in patients with relapsed/refractory FLT3-ITD-mutated acute myeloid leukemia (AML). Patients with RAS/MAPK and FLT3-F691L mutations...
